IQC	INITIALS	DATE
Cut		
Labelled		
Collated		
QC		
Packaged		

HEALTH SERVICES LABORATORIES
ADVANCED DIAGNOSTICS

Address: HSL-AD, Ground Floor, 60 Whitfield Street, London, W1T 4EU
Tel: +44 (0)20 3912 0280 | **Email:** AD@hslpathology.com | **Web:** www.hsl-ad.com

PD-L1 IHC (PEMBROLIZUMAB, Agilent pharmDx 22C3, UROTHELIAL CA, CPS)

FOR LABORATORY USE ONLY

HSL-AD NUMBER:_____ MATERIAL RECEIVED:_____

PRICE (TO BE INVOICED):_____ DATE RECEIVED & INITIALS:_____

PATIENT / SAMPLE DETAILS

SURNAME:_____ SURGICAL CASE ID:_____

FORENAME:_____ TUMOUR TYPE & GRADE:_____

DOB:_____ M ☐ F ☐

REFERRING HOSPITAL / INVOICING DETAILS

CONSULTANT:_____

ADDRESS:_____

_____

_____

PHONE:_____

INVOICING DETAILS (if different)

CONTACT NAME:_____

ORGANISATION:_____

ADDRESS:_____

_____

PURCHASE NUMBER:_____

REPORT DELIVERY (please tick - faxing of reports will end October 2020) FAX ☐ EMAIL ☐

FAX NUMBER(S):	EMAIL ADDRESS(ES):
_____	_____
_____	_____

PD-L1 (PEMBROLIZUMAB, Agilent 22C3 pharmDx, UROTHELIAL CARCINOMA) CPS IHC REPORT

TUMOUR ASSESSMENT

☐ SUFFICIENT FOR ASSESSMENT

☐ INSUFFICIENT FOR ASSESSMENT

COMBINED POSITIVE SCORE

☐ COMBINED POSITIVE SCORE

RESULT

☐ **NEGATIVE** *(<10 CPS)*

☐ **POSITIVE** *(≥10 CPS)*

TEST COMMENTS

INTERPRETATION GUIDE: **This assay is FDA-approved and uses the Dako pharmDx 22C3 kit stained on the Dako Autostainer Link48. This report is for use in Urothelial Carcinoma only and is used as a companion diagnostic to indicate the suitability of patient treatment with Pembrolizumab. Scoring method used is the Combined Positive Score (CPS). Use of this report for selection of treatment options in other tumour settings has not been validated. The use of Pembrolizumab is currently not licensed by NICE.**

NEGATIVE (<10): Patient is unlikely to respond to treatment involving Pembrolizumab.

POSITIVE (≥10): Patient may respond to treatment involving Pembrolizumab.

SIGNED:_____ **DATE:**_____

Dr Rebecca Gillibrand / Dr Ian Proctor